LINC02389: A Potential Drug Target and Biomarker (G400046)

Target Name: LINC02389

NCBI ID: G400046

LINC02389

Other Name(s): Long intergenic non-protein coding RNA 2389 | long intergenic non-protein coding RNA 2389

LINC02389: A Potential Drug Target and Biomarker

Non-protein coding RNAs (ncRNAs) have emerged as a promising source of drug targets and biomarkers due to their diverse functions in various cellular processes. One such RNA, LINC02389, has shown promising potential as a drug target and biomarker in various cellular pathways, including cancer, neurodegenerative diseases, and autoimmune disorders.

LINC02389 is a non-coding RNA molecule that was identified using RNA sequencing (RNA-seq) data. It was found to have a unique expression pattern in various tissues and cells, including brain, muscle, and pancreatic tissues, and was named as LINC02389 . The RNA-seq data revealed that LINC02389 was expressed at different levels in these tissues and cells, with the highest expression levels observed in the brain.

The structure of LINC02389 was determined using computational tools, and it showed a conserved core structure with a unique N-terminal region that was not conserved in any known protein or RNA molecule. The conserved N-terminal region contains a unique GCAATGCA sequence that is similar to the conserved GCAATGCC motif found in various proteins, such as the protein kinase Akt1.

To determine the function of LINC02389, various experiments were performed to investigate its localization and interaction with protein targets in various cellular pathways. Using RNA-seq data, it was found that LINC02389 was highly expressed in the brain, and its expression levels were highest in the cortical regions. This suggests that LINC02389 may play a role in the development and progression of certain neurological disorders.

Furthermore, to study its interaction with protein targets, LINC02389 was co-expressed with several well-known protein molecules, including the transcription factor NF-kappa-B, the protein kinase activating receptor activating receptor PDGFR-尾, and the transcription factor ASXL1. RNA-seq data showed that LINC02389 was highly co-expressed with these proteins and that they were involved in various cellular processes, including cell growth, migration, and survival.

To determine its potential as a drug target, LINC02389 was targeted for inhibition using small interfering RNA (siRNA) screening. siRNA screening revealed that LINC02389 was a good candidate for a drug target due to its high expression level and its involvement in various cellular processes that are relevant to drug targets.

Several studies have investigated the effects of LINC02389 inhibitors on various cellular processes, including cell growth, apoptosis, and transcriptional regulation. For example, a study by Zhao et al. (2018) investigated the effects of LINC02389 inhibitors on the growth of cancer cells and found that these inhibitors significantly reduced the cell proliferation of cancer cells, suggesting that LINC02389 may be a useful drug target for cancer treatment.

Another study by Wang et al. (2019) investigated the effects of LINC02389 inhibitors on the expression of genes involved in cell apoptosis and found that these inhibitors significantly reduced the expression of genes involved in cell apoptosis, suggesting that LINC02389 may be involved in the regulation of cell apoptosis.

In addition to its potential as a drug target, LINC02389 has also been investigated as a biomarker for various diseases. For example, a study by Zhang et al. (2020) investigated the relationship between LINC02389 expression and clinical outcomes in patients with pancreatic ductal adenocarcinoma , a common form of pancreatic cancer. The results showed that LINC02389 expression was significantly associated with poor prognosis in patients with pancreatic ductal adenocarcinoma, suggesting that LINC02389 may be a useful biomarker for this disease.

In conclusion, LINC02389 is a non-protein coding RNA molecule that has shown promising potential as a drug target and biomarker. Its unique expression pattern and conserved N-terminal region make it a promising candidate for drug targeting, while its involvement in various cellular processes and its potential as a biomarker for diseases make it a promising target for future research. Further studies are needed to fully understand its function and potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2389

The "LINC02389 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02389 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets